Exclusive Summary

• **Guideline-Endorsed Gold Standard:** Strongly recommended by NCCN/ESMO guidelines as first-line therapy for uHCC and DTC, ensuring massive and stable global prescription demand.
• **High Technical Barriers:** Complex formulation challenges regarding solubility limit the number of qualified competitors, making ready-to-license FDFs with BE data a scarce asset.
• **Patent Circumvention Strategy:** Offering non-infringing formulation technologies enables partners to navigate patent thickets and secure 'First-to-Market' opportunities in target regions.
• **Competitive Cost Structure:** Leveraging China's integrated supply chain delivers distinct cost advantages, allowing aggressive pricing against the originator in price-sensitive global markets.

Asset Materials

Contact Us for Full Materials